Genscript Biotech (HKG:1548) returned to an attributable profit of $2.96 billion in 2024, compared with a loss of $95.5 million in the prior year, according to a Wednesday filing with the Hong Kong bourse.
The recovery came as the company booked a $3.2 billion gain from the deconsolidation of its cell therapy business.
Earnings per share were $1.3597, compared with a loss per share of $0.0453 a year ago. Seven visible Alpha analysts expected a loss per share of $0.07.
Revenue for the year rose 6.1% to $594.5 million from $560.5 million in the previous year. Visible Alpha estimated an annual revenue of $574.1 million.
The bioscience firm shares were almost 4% down in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.